Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part ...

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...
WPRI 12

Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)

Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally ...
GEN

REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III

When the FDA approved Spark Therapeutics’ Luxturna in December 2017, gene therapy became a household concept. Chatter about gene therapy curing blindness became hot fodder at dinner tables and ...
WCBD

Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis

The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling male patients ages 6-64 with RS1-associated XLRS ATSN-201 leverages novel spreading ...
News Medical

New robotic surgery device aims to enhance precision in retinal procedures

When even the most highly trained surgeons perform procedures on the retina-one of the smallest, most delicate parts of the human body-the stakes are high. Surgeons must account for patients' ...